首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 以基因為基之藥物開發

市場調查報告書

商品編碼

1169177

表觀遺傳學藥物和診斷技術市場:按類型（表觀遺傳學藥物,（DNMT抑製劑、HDAC抑製劑,其他）,表觀遺傳學診斷技術）,地區規模,份額,前景,機會分析2022-2030

Epigenetics Drugs & Diagnostic Technologies Market, by Type (Epigenetic Drugs, (DNMT Inhibitors, HDAC Inhibitors and Others) and Epigenetics Diagnostic Technologies and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年11月08日 | 出版商:

Coherent Market Insights | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

表觀遺傳學是一門以化學方式改變生物體內特定基因的學科。表觀遺傳學藥物用於逆轉導致多種疾病的基因表達異常，包括癌症、心髒病、糖尿病和精神疾病。癌症患病率的上升、生物技術行業投資的增加以及新藥分子研發的增加預計將在預測期內推動市場增長。

市場動態

預計癌症患病率的增加將推動預測期內的市場增長。

根據世界衛生組織的數據，癌症是全球死亡的主要原因，2020 年約有 1000 萬人死於癌症。乳腺癌（226萬例）、肺癌（221萬例）和結直腸癌（193萬例）的癌症新發病例數最多。

表觀遺傳改變通常與所有人類癌症相關，並且通常是導致癌症表型的遺傳改變的原因。表觀遺傳改變包括組蛋白修飾劑和閱讀器、脫氧核糖核酸 (DNA) 甲基化、染色質重塑劑和染色質的其他成分。表觀遺傳變化可導致基因突變，最終導致表觀基因組變化。

表觀遺傳藥物的作用是幫助逆轉這些表觀遺傳變化。表觀遺傳療法通常用於治療實體瘤和其他癌症。

這項研究的主要特點

本報告以2021年為基準年，分析了預測期內（2022-2030年）的全球表觀遺傳藥物和診斷技術市場、市場規模（百萬美元）和復合年增長率（CAGR%）細節。
解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
它還提供了有關市場驅動因素、制約因素、機會、新產品發布和批准、市場趨勢、區域前景以及主要參與者採用的競爭戰略的重要見解。
根據公司亮點、產品組合、主要亮點、財務業績和戰略等參數介紹全球表觀遺傳學製藥和診斷技術市場主要參與者的概況。
本研究涉及的主要公司有:Regenacy Pharmaceuticals, Inc.、Astex Pharmaceuticals、4SC AG、CellCentric Ltd.、Celleron Therapeutics Ltd.、Bristol-Myers Squibb Company、Oryzon Genomics S.A.、ChromaMedicine, Inc.、Epizyme , Inc. 和 EpiGentek Group Inc.
這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
《全球表觀遺傳學藥物和診斷技術市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者將能夠通過用於分析全球表觀遺傳藥物和診斷技術市場的各種戰略矩陣來促進他們的決策。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第二章市場展望

報告內容
- 市場定義和範圍
執行摘要
- 市場細分:按類型
- 按地區劃分的市場細分
連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

司機
約束因素
商機
影響分析
主要亮點
產品發布和批准
害蟲分析
技術進步
監管場景
併購、合作

第 4 章表觀遺傳學藥物和診斷技術的全球市場:冠狀病毒 (COVID-19) 大流行的影響

經濟影響
COVID-19 的流行病學特徵
對錶觀遺傳學和診斷試劑供需的影響

第 5 章表觀遺傳藥物和診斷的全球市場:按類型，2017-2030

表觀遺傳藥物
DNMT抑製劑
HDAC 抑製劑
其他
表觀遺傳學診斷技術
DNA甲基化
芯片技術

第 6 章 2017 年至 2030 年按地區分列的全球表觀遺傳學和診斷市場

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
德國
英國
法國
意大利
西班牙
俄羅斯
其他歐洲地區
亞太地區
中國
印度
日本
澳大利亞
韓國
東盟
其他亞太地區
中東
海灣合作委員會
以色列
其他中東地區
非洲
南非
中非
北非

第七章競爭格局

競爭快照
- Regenacy Pharmaceuticals, Inc.
- Astex Pharmaceuticals
- 4SC AG
- CellCentric Ltd.
- Celleron Therapeutics Ltd.
- Bristol-Myers Squibb Company
- Oryzon Genomics S.A.
- ChromaMedicine, Inc.
- Epizyme, Inc.
- EpiGentek Group Inc.

第 8 章

參考文獻
調查方法

簡介目錄

Product Code: CMI4026

Epigenetics is the study of chemical modifications of some specific genes of an organism. Epigenetic drugs are used to reverse the abnormal gene expression which leads to different types of diseases such as cancer, heart disease, diabetes, and mental illnesses. Increasing prevalence of cancer, increasing research and development for new drug molecule along with increasing investment in biotechnology industry is expected to propel market growth during the forecasted period.

Market Dynamics

Increasing prevalence of cancer is expected to drive the market growth during the forecast period.

According to the World Health Organization, cancer is a leading cause of death worldwide, which accounted for around 10 million deaths in 2020. The most common cancer, in terms of new cases of cancer were breast (2.26 million cases), lung (2.21 million cases) and colon & rectum (1.93 million cases).

Epigenetic changes are commonly associated with all human cancers and often responsible for genetic alterations driving the cancer phenotype. The changes includes histone modifiers and readers, Deoxyribonucleic acid (DNA) methylation, chromatin remodelers, and other components of chromatin. The epigenetic changes can lead to mutations in genes which eventually causes modification of the epigenome.

The function of epigenetic drugs in that they help in reversing these epigenetic changes. Epigenetic therapies are often used in the treatment of solid tumors and other types of cancer.

Key features of the study:

This report provides an in-depth analysis of the global epigenetics drugs & diagnostic technologies market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global epigenetics drugs & diagnostic technologies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Regenacy Pharmaceuticals, Inc., Astex Pharmaceuticals, 4SC AG, CellCentric Ltd., Celleron Therapeutics Ltd., Bristol-Myers Squibb Company, Oryzon Genomics S.A., ChromaMedicine, Inc., Epizyme, Inc., and EpiGentek Group Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global epigenetics drugs & diagnostic technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epigenetics drugs & diagnostic technologies market

Detailed Segmentation:

Global Epigenetics Drugs & Diagnostic Technologies Market, By Type:
- Epigenetic Drugs
  - DNMT Inhibitors
  - Azacitidine
  - Decitabine
  - HDAC Inhibitors
  - Vorinostat
  - Romidepsin
  - Others
- Epigenetics Diagnostic Technologies
  - DNAMethylation
  - CHIP Technology
Global Epigenetics Drugs & Diagnostic Technologies Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region
- South Africa
- Central Africa
- North Africa
Company Profiles
- Regenacy Pharmaceuticals, Inc.*
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Astex Pharmaceuticals
- 4SC AG
- CellCentric Ltd.
- Celleron Therapeutics Ltd.
- Bristol-Myers Squibb Company
- Oryzon Genomics S.A.
- ChromaMedicine, Inc.
- Epizyme, Inc.
- EpiGentek Group Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Type
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunity
Impact Analysis
Key Highlights
Product Launch/Approvals
PEST Analysis
Technological Advancements
Regulatory Scenario
Mergers, Acquisitions and Collaborations

4. Global Epigenetic Drugs & Diagnostic Technologies Market - Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand of Epigenetics Drugs & Diagnostic Products

5. Global Epigenetic Drugs & Diagnostic Technologies Market, By Type, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Epigenetic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
DNMT Inhibitors
- Azacitidine
- Decitabine
HDAC Inhibitors
- Vorinostat
- Romidepsin
Others
Epigenetics Diagnostic Technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
DNAMethylation
CHIP Technology

6. Global Epigenetic Drugs & Diagnostic Technologies Market, By Region, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
North America
- Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 - 2030, (US$ Mn)
South Africa
Central Africa
North Africa